Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

KBP Biosciences discloses novel mineralocorticoid receptor antagonists

Oct. 17, 2012

FDA accepts Serada NDA for filing

Oct. 16, 2012

Teijin Pharma presents novel CaSR antagonists with promising in vivo activity

Oct. 16, 2012

Novel GPR119 receptor agonists prepared by Boehringer Ingelheim and Neurocrine Biosciences

Oct. 15, 2012

Roche synthesizes new HSL inhibitors

Oct. 15, 2012

Zafgen presents novel MetAP 2 inhibitors for obesity

Oct. 11, 2012

Significant reduction of HbA1c seen with VRS-859 in clinical trial

Oct. 11, 2012

Phase I and II data presented for semaglutide

Oct. 11, 2012

Ajinomoto to study nateglinide in combination with DPP IV inhibitor

Oct. 10, 2012

European Commission approves Bayer Healthcare's Flexyess

Oct. 10, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...
GSK’s newly acquired Jideytro wins FDA nod in NSCLC
BioWorld
About a week after closing its $10.6 billion acquisition of Nuvalent Inc., GSK plc has reaped the first reward, announcing U.S. FDA approval of zidesamtinib in...
Korea targets generics, innovation in drug pricing overhaul
BioWorld
South Korea is moving ahead with its biggest reform of drug review and pricing in more than a decade, reflecting a wider shift across Asian markets to reward...